Investing.com - Novo Nordisk ADR (NYSE: NVO) reported first quarter EPS of $5.68, $4.93 better than the analyst estimate of $0.75. Revenue for the quarter came in at $65.35B versus the consensus estimate of $9.14B.
Novo Nordisk ADR's stock price closed at $129.22. It is up 13.65% in the last 3 months and up 54.04% in the last 12 months.
Novo Nordisk ADR saw positive EPS revisions and negative EPS revisions in the last 90 days. See Novo Nordisk ADR's stock price’s past reactions to earnings here.
According to InvestingPro, Novo Nordisk ADR's Financial Health score is "great performance".
Check out Novo Nordisk ADR's recent earnings performance, and Novo Nordisk ADR's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
Should you invest $2,000 in NVO right now?
ProPicks AI are 6 model portfolios created by Investing.com which identify the best stocks for investors to buy now. The stocks that made the cut could produce monster returns in the coming years. Is NVO one of them?
Unlock ProPicks AI to find out